ClinicalTrials.gg
CompletedNCT03517449Updated Mar 19, 2026Results posted

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

A Phase 3 interventional study of Pembrolizumab and Lenvatinib in Endometrial Neoplasms, sponsored by Eisai Inc.. Completed at 169 sites in 21 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
827
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing pembrolizumab in Endometrial Neoplasms — 5 open to participants now, 12 under way, 5 of them phase 3. pembrolizumab · Endometrial Neoplasms.

Enrollment
4th of 25
827 · median 46
Started
2018
with 1 other
Phase 3
8 of 25
2 open now
Registered
10th of 25
by date
Lead sponsor
1 of 25
Eisai Inc.

Among the 25 studies testing pembrolizumab in Endometrial Neoplasms, this one is the 4th largest by enrollment, is one of 2 that started in 2018, is one of 8 in phase 3, and was the 10th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

5 of the 25 studies testing pembrolizumab in Endometrial Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing pembrolizumab in Endometrial Neoplasms, or all of them as a file.
02

Study summary

This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to receive either pembrolizumab and lenvatinib or treatment of physician's choice. The primary study hypothesis is that pembrolizumab in combination with lenvatinib prolongs progression free survival (PFS) and overall survival (OS) when compared to treatment of physician's choice.

03

Conditions studied

  • Endometrial Neoplasms

Keywords

  • programmed cell death 1 (PD-1, PD1)
  • programmed cell death ligand 1 (PD-L1, PDL1)
  • programmed cell death ligand 2 (PD-L2, PDL2)
  • vascular endothelial growth factor (VEGF) receptors
  • lenvatinib
  • pembrolizumab
  • doxorubicin
  • paclitaxel
  • phase 3 endometrial cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has a confirmed diagnosis of endometrial carcinoma (EC)
  2. Documented evidence of advanced, recurrent or EC.
  3. Has radiographic evidence of disease progression after 1 prior systemic, platinum-based chemotherapy regimen for EC. Participants may have received up to 1 additional line of platinum-based chemotherapy if given in the or adjuvant treatment setting.

    Note: There is no restriction regarding prior hormonal therapy.

  4. Has historical or fresh tumor specimen for determination of mismatch repair (MMR) status.
  5. Has at least 1 measurable target lesion according to (RECIST) 1.1 and confirmed by Blinded Independent Central Review BICR.
  6. Has (ECOG) performance status of 0 or 1 within 7 days of starting study treatment.
  7. Is not pregnant, breastfeeding, and agrees to use a highly effective method of during the treatment period and for at least 120 days (for participants treated with lenvatinib plus pembrolizumab) or at least 180 days (for participants treated with treatment of physician's choice [TPC]) after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Has carcinosarcoma (malignant mixed mullerian tumor), endometrial leiomyosarcoma and endometrial stromal sarcomas.
  2. Has unstable central nervous system (CNS) .
  3. Has active (except for endometrial cancer, definitively treated in-situ carcinomas [e.g. breast, cervix, bladder], or basal or squamous cell carcinoma of the skin) within 24 months of study start.
  4. Has gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib.
  5. Has a pre-existing greater than or equal (>=) Grade 3 gastrointestinal or non-gastrointestinal fistula.
  6. Has radiographic evidence of major blood vessel invasion/infiltration.
  7. Has hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study treatment.
  8. Has a history of congestive heart failure greater than (NYHA) Class II, unstable angina, myocardial infarction, cerebrovascular accident (CVA) stroke, or cardiac arrhythmia associated with hemodynamic instability within 12 months of the first dose of study treatment.
  9. Has an active infection requiring systemic treatment.
  10. Has not recovered adequately from any toxicity and/or complications from major surgery prior to starting therapy.
  11. Is positive for (HIV).
  12. Has active or C.
  13. Has a history of (non-infectious) pneumonitis that required treatment with , or has current pneumonitis.
  14. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
  15. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to study start -Has an active disease (with the exception of psoriasis) that has required systemic treatment in the past 2 years.
  16. Is pregnant or breastfeeding.
  17. Has had an allogenic tissue/solid organ transplant.
  18. Has received >1 prior systemic chemotherapy regimen (other than adjuvant or ) for Endometrial Cancer. Participants may receive up to 2 regimens of platinum-based chemotherapy in total, as long as one is given in the neoadjuvant or adjuvant treatment setting.
  19. Has received prior anticancer treatment within 28 days of study start. All acute toxicities related to prior treatments must be resolved to Grade ≤1, except for alopecia and Grade ≤2 peripheral neuropathy.
  20. Has received prior treatment with any treatment targeting VEGF-directed angiogenesis, any , anti-PD-L1, or anti-PD-L2 agent.
  21. Has received prior treatment with an agent directed to a stimulatory or co-inhibitory T-cell receptor other than an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, and who has discontinued from that treatment due to a Grade 3 or higher immune-related adverse event.
  22. Has received prior radiation therapy within 21 days of study start with the exception of palliative radiotherapy to bone lesions, which is allowed if completed 2 weeks of study start. Participants must have recovered from all radiation-related toxicities and/or complications prior to randomization.
  23. Has received a within 30 days of study start.
  24. Has a known intolerance to study treatment (or any of the ).
  25. Prior enrollment on a clinical study evaluating pembrolizumab and lenvatinib for endometrial carcinoma, regardless of treatment received.
  26. Is currently participating in or has participated in a study of an agent or has used an investigational device within 4 weeks of study start.
  27. Participants with urine protein ≥1 gram (g)/24 hour.
  28. Prolongation of (QTc) interval to >480 milliseconds (ms).
  29. (LVEF) below the institutional normal range as determined by multigated acquisition scan (MUGA) or echocardiogram (ECHO).
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
827 participants (actual)

Study arms

  • Experimental
    Lenvatinib 20 mg + Pembrolizumab 200 mg

    Participants will receive pembrolizumab 200 milligram (mg) administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus lenvatinib 20 mg administered orally (PO) once daily (QD) during each 21-day cycle for up to 35 cycles.

    Drug: Pembrolizumab · Drug: Lenvatinib

  • Active comparator
    Treatment of Physician's Choice

    Participants will receive either of the following treatments: doxorubicin 60 milligram per square meter (mg/m\^2) administered by IV on Day 1 of each 21-day cycle for up to a maximum cumulative dose of 500 mg/m\^2 OR paclitaxel 80 mg/m\^2 administered by IV on a 28-day cycle: 3 weeks receiving paclitaxel once a week and 1 week not receiving paclitaxel.

    Drug: Paclitaxel · Drug: Doxorubicin

Interventions

  • 200 mg administered by IV infusion on Day 1 of each 21-day cycle.

    Also known as: KEYTRUDA®, MK-3475

  • 20 mg administered orally (PO) QD during each 21-day cycle.

    Also known as: LENVIMA®

  • 80 mg/m\^2 administered by IV on a 28-day cycle: 3 weeks receiving paclitaxel once a week and 1 week not receiving paclitaxel.

    Also known as: TAXOL®

  • 60 mg/m\^2 administered by IV on Day 1 of each 21-day cycle.

    Also known as: ADRIAMYCIN®

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants

    PFS was defined as the time from the date of randomization to the date of the first documentation of disease progression, as determined by Blinded Independent Central Review (BICR) per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death due to any cause (whichever occurred first). Disease progression was defined as at least 20 percent (%) increase (including an absolute increase of at least 5 millimeter \[mm\]) in the sum of diameter of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. PFS was estimated and analyzed using Kaplan-Meier method.

    Time frame: Up to approximately 27 months

  2. PFS Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on BICR in All-comer Participants

    PFS was defined as the time from the date of randomization to the date of the first documentation of disease progression, as determined by Blinded Independent Central Review (BICR) per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death due to any cause (whichever occurred first). Disease progression was defined as at least 20 percent (%) increase (including an absolute increase of at least 5 millimeter \[mm\]) in the sum of diameter of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. PFS was estimated and analyzed using Kaplan-Meier method.

    Time frame: Up to approximately 27 months

  3. Overall Survival (OS) in pMMR Participants

    OS was defined as the time from the date of randomization to the date of death due to any cause. Participants who were lost to follow-up and those who were alive at the date of data cut-off were censored at the date the participant was last known alive, or date of data cut-off, whichever occurred first.

    Time frame: Up to approximately 43 months

  4. OS in All-comer Participants

    OS was defined as the time from the date of randomization to the date of death due to any cause. Participants who were lost to follow-up and those who were alive at the date of data cut-off were censored at the date the participant was last known alive, or date of data cut-off, whichever occurred first.

    Time frame: Up to approximately 43 months

Secondary outcomes

  1. Objective Response Rate (ORR) in pMMR Participants

    ORR was defined as the percentage of participants who had best overall response of either complete response (CR) or partial response (PR) as determined by BICR per RECIST 1.1. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<) 10mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

    Time frame: Up to approximately 80 months

  2. ORR in All-comer Participants

    ORR was defined as the percentage of participants who had best overall response of either complete response (CR) or partial response (PR) as determined by BICR per RECIST 1.1. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<) 10mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

    Time frame: Up to approximately 80 months

  3. Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) in pMMR Participants

    EORTC QLQ-C30 was a questionnaire which included 30 questions that rates the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Scores are transformed to a range of 0 to 100 using a standard EORTC algorithm. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem.

    Time frame: Baseline, Week 12

  4. Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) in All-comer Participants

    EORTC QLQ-C30 was a questionnaire which included 30 questions that rates the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Scores are transformed to a range of 0 to 100 using a standard EORTC algorithm. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem.

    Time frame: Baseline, Week 12

  5. Number of Partricipants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Immune-Related Adverse Events (irAEs)

    TEAEs were AEs that occurred (or worsened, if present at baseline) after the first dose of study drug through 28 days after the last dose. An AE was any untoward medical occurrence in a participant temporally associated with use of study treatment, whether or not related to the treatment. An SAE was any untoward medical occurrence at any dose that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, or was a congenital anomaly/birth defect. An irAE was any unfavorable and unintended immune-related sign, symptom, or disease (new or worsening) temporally associated with study therapy, regardless of whether a causal relationship with the therapy could be determined.

    Time frame: Up to approximately 77 months

  6. Number of Participants Who Discontinued Study Treatment Due to a TEAE in pMMR Participants

    TEAEs was defined as those AEs that occurred (or worsened, if present at Baseline) after the first dose of study drug through 30 days after the last dose of study drug. An AE was defined as any untoward medical occurrence in a participants or clinical study participant temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Up to approximately 77 months

  7. Number of Participants Who Discontinued Study Treatment Due to a TEAE in All-comer Participants

    TEAEs was defined as those AEs that occurred (or worsened, if present at Baseline) after the first dose of study drug through 30 days after the last dose of study drug. An AE was defined as any untoward medical occurrence in a participants or clinical study participant temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Up to approximately 77 months

  8. Time to Treatment Failure Due to Toxicity in pMMR Participants

    Time to treatment failure due to toxicity was defined as the time from the date of randomization to the date a participant discontinued study treatment due to TEAEs.

    Time frame: Up to approximately 77 months

  9. Time to Treatment Failure Due to Toxicity in All-comer Participants

    Time to treatment failure due to toxicity was defined as the time from the date of randomization to the date a participant discontinued study treatment due to TEAEs.

    Time frame: Up to approximately 77 months

  10. Plasma Concentration of Lenvatinib Versus Time in All-comer Participants

    Pharmacokinetic (PK) samples were collected and analyzed using a population PK approach to estimate PK parameters. Individual predicted plasma concentration of lenvatinib was then derived from the PK model.

    Time frame: Cycle 1 day 1 0.5-4 hours (h), 6-10 postdose; Cycle 1 day 15 predose; Cycle 1 day 15 2-12h postdose, Cycle 2 day 1 predose, 0.5-4h, 6-10 h (Each cycle is 21 days)

  11. Plasma Concentration of Lenvatinib Versus Time in pMMR Participants

    PK samples were collected and analyzed using a population PK approach to estimate PK parameters. Individual predicted plasma concentration of lenvatinib was then derived from the PK model.

    Time frame: Cycle 1 day 1 0.5-4 hour (h), 6-10 postdose; Cycle 1 day 15 predose; Cycle 1 day 15 2-12h postdose, Cycle 2 day 1 predose, 0.5-4h, 6-10 h (Each cycle is 21 days)

  12. Model Predicted Apparent Total Clearance (CL/F) for Lenvatinib

    Sparse pharmacokinetic (PK) samples were collected and analyzed using a population PK approach to estimate PK parameters. Individual predicted CL/F for lenvatinib was then derived from the PK model. The data was collected and analyzed for lenvatinib plus pembrolizumab arm only.

    Time frame: Cycle 1 Day 1: 0.5-10 hours post-dose; Cycle 1 Day 15: 0-12 hours post-dose; Cycle 2 Day 1: 0.5-10 hours post-dose (each cycle length=21 days)

  13. Model Predicted Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib

    Sparse PK samples were collected and analyzed using a population PK approach to estimate PK parameters. Individual predicted AUC for lenvatinib was then derived from the PK model. The data was collected and analyzed for lenvatinib plus pembrolizumab arm only.

    Time frame: Cycle 1 Day 1: 0.5-10 hours post-dose; Cycle 1 Day 15: 0-12 hours post-dose; Cycle 2 Day 1: 0.5-10 hours post-dose (each cycle length=21 days)

07

Results

Posted Nov 17, 2021

Participant flow

Participants took part in the study at 167 investigative sites in Argentina, Australia, Brazil, Canada, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Mexico, New Zealand, Poland, Russia, Spain, Taiwan, Turkey, United Kingdom and the United States

Participant flow — Overall Study
MilestoneLenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel
Started411416
Completed411416
Not completed00

Outcome measures

PrimaryProgression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants

PFS was defined as the time from the date of randomization to the date of the first documentation of disease progression, as determined by Blinded Independent Central Review (BICR) per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death due to any cause (whichever occurred first). Disease progression was defined as at least 20 percent (%) increase (including an absolute increase of at least 5 millimeter \[mm\]) in the sum of diameter of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. PFS was estimated and analyzed using Kaplan-Meier method.

Time frame:
Up to approximately 27 months
Reported as:
Median · Months
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants
MonthsLenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants6.6 ± 5.63.8 ± 3.6
Statistical analysis
  • Lenvatinib 20 mg + Pembrolizumab 200 mg vs Treatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel · Log Rank · p = < 0.0001 (One-sided p-value based on log-rank test stratified by ECOG performance status, geographic region, and prior history of pelvic radiation.) · Hazard ratio (hr): 0.60 · 95% CI 0.50 to 0.72Regression, Cox method
PrimaryPFS Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on BICR in All-comer Participants

PFS was defined as the time from the date of randomization to the date of the first documentation of disease progression, as determined by Blinded Independent Central Review (BICR) per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death due to any cause (whichever occurred first). Disease progression was defined as at least 20 percent (%) increase (including an absolute increase of at least 5 millimeter \[mm\]) in the sum of diameter of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. PFS was estimated and analyzed using Kaplan-Meier method.

Time frame:
Up to approximately 27 months
Reported as:
Median · Months
PFS Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on BICR in All-comer Participants
MonthsLenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel
PFS Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on BICR in All-comer Participants7.2 ± 5.73.8 ± 3.6
Statistical analysis
  • Lenvatinib 20 mg + Pembrolizumab 200 mg vs Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel · Log Rank · p = < 0.0001 (One-sided p-value based on log-rank test stratified by ECOG performance status, geographic region, and prior history of pelvic radiation.) · Hazard ratio (hr): 0.56 · 95% CI 0.47 to 0.66Regression, Cox method
PrimaryOverall Survival (OS) in pMMR Participants

OS was defined as the time from the date of randomization to the date of death due to any cause. Participants who were lost to follow-up and those who were alive at the date of data cut-off were censored at the date the participant was last known alive, or date of data cut-off, whichever occurred first.

Time frame:
Up to approximately 43 months
Reported as:
Median · Months
Overall Survival (OS) in pMMR Participants
MonthsLenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel
Overall Survival (OS) in pMMR Participants18.0 (14.9 to 20.5)12.2 (11.0 to 14.1)
Statistical analysis
  • Lenvatinib 20 mg + Pembrolizumab 200 mg vs Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel · Log Rank · p = < 0.0001 (One-sided p-value based on log-rank test stratified by ECOG performance status, geographic region, and prior history of pelvic radiation.) · Hazard ratio (hr): 0.70 · 95% CI 0.58 to 0.83
PrimaryOS in All-comer Participants

OS was defined as the time from the date of randomization to the date of death due to any cause. Participants who were lost to follow-up and those who were alive at the date of data cut-off were censored at the date the participant was last known alive, or date of data cut-off, whichever occurred first.

Time frame:
Up to approximately 43 months
Reported as:
Number · Months
OS in All-comer Participants
MonthsLenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel
OS in All-comer Participants18.7 ± 15.611.9 ± 10.7
Statistical analysis
  • Lenvatinib 20 mg + Pembrolizumab 200 mg vs Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel · Log Rank · p = < 0.0001 (One-sided p-value based on log-rank test stratified by ECOG performance status, geographic region, and prior history of pelvic radiation.) · Hazard ratio (hr): 0.65 · 95% CI 0.55 to 0.77
SecondaryObjective Response Rate (ORR) in pMMR Participants

ORR was defined as the percentage of participants who had best overall response of either complete response (CR) or partial response (PR) as determined by BICR per RECIST 1.1. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<) 10mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

Time frame:
Up to approximately 80 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) in pMMR Participants
Percentage of participantsLenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel
Objective Response Rate (ORR) in pMMR Participants30.3 ± 25.515.1 ± 11.5
Statistical analysis
  • Lenvatinib 20 mg + Pembrolizumab 200 mg vs Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel · Miettinen & Nurminen method · p = < 0.0001 · Difference in percentage: 15.2 · 95% CI 9.1 to 21.4
SecondaryORR in All-comer Participants

ORR was defined as the percentage of participants who had best overall response of either complete response (CR) or partial response (PR) as determined by BICR per RECIST 1.1. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<) 10mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

Time frame:
Up to approximately 80 months
Reported as:
Number · Percentage of Participants
ORR in All-comer Participants
Percentage of ParticipantsLenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel
ORR in All-comer Participants31.9 ± 27.414.7 ± 11.4
Statistical analysis
  • Lenvatinib 20 mg + Pembrolizumab 200 mg vs Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel · Miettinen & Nurminen method · p = < 0.0001 · Difference in percentage: 17.2 · 95% CI 11.5 to 22.9
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) in pMMR Participants

EORTC QLQ-C30 was a questionnaire which included 30 questions that rates the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Scores are transformed to a range of 0 to 100 using a standard EORTC algorithm. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) in pMMR Participants
Score on a scaleLenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) in pMMR Participants-6.80 ± -9.43-7.96 ± -10.86
Statistical analysis
  • Lenvatinib 20 mg + Pembrolizumab 200 mg vs Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel · cLDA model · p = = 0.5316 · Difference in ls means: 1.16 · 95% CI -2.49 to 4.81
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) in All-comer Participants

EORTC QLQ-C30 was a questionnaire which included 30 questions that rates the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Scores are transformed to a range of 0 to 100 using a standard EORTC algorithm. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) in All-comer Participants
Score on a scaleLenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) in All-comer Participants-5.97 ± -8.36-6.98 ± -9.63
Statistical analysis
  • Lenvatinib 20 mg + Pembrolizumab 200 mg vs Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel · cLDA model · p = = 0.5460 · Difference in ls means: 1.01 · 95% CI -2.28 to 4.31
SecondaryNumber of Partricipants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Immune-Related Adverse Events (irAEs)

TEAEs were AEs that occurred (or worsened, if present at baseline) after the first dose of study drug through 28 days after the last dose. An AE was any untoward medical occurrence in a participant temporally associated with use of study treatment, whether or not related to the treatment. An SAE was any untoward medical occurrence at any dose that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, or was a congenital anomaly/birth defect. An irAE was any unfavorable and unintended immune-related sign, symptom, or disease (new or worsening) temporally associated with study therapy, regardless of whether a causal relationship with the therapy could be determined.

Time frame:
Up to approximately 77 months
Reported as:
Count of participants · Participants
Number of Partricipants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Immune-Related Adverse Events (irAEs)
ParticipantsLenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel
Number of Partricipants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Immune-Related Adverse Events (irAEs)237121
SecondaryNumber of Participants Who Discontinued Study Treatment Due to a TEAE in pMMR Participants

TEAEs was defined as those AEs that occurred (or worsened, if present at Baseline) after the first dose of study drug through 30 days after the last dose of study drug. An AE was defined as any untoward medical occurrence in a participants or clinical study participant temporally associated with the use of study treatment, whether or not considered related to the study treatment.

Time frame:
Up to approximately 77 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to a TEAE in pMMR Participants
ParticipantsLenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel
Number of Participants Who Discontinued Study Treatment Due to a TEAE in pMMR Participants14042
SecondaryNumber of Participants Who Discontinued Study Treatment Due to a TEAE in All-comer Participants

TEAEs was defined as those AEs that occurred (or worsened, if present at Baseline) after the first dose of study drug through 30 days after the last dose of study drug. An AE was defined as any untoward medical occurrence in a participants or clinical study participant temporally associated with the use of study treatment, whether or not considered related to the study treatment.

Time frame:
Up to approximately 77 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to a TEAE in All-comer Participants
ParticipantsLenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel
Number of Participants Who Discontinued Study Treatment Due to a TEAE in All-comer Participants18049
SecondaryTime to Treatment Failure Due to Toxicity in pMMR Participants

Time to treatment failure due to toxicity was defined as the time from the date of randomization to the date a participant discontinued study treatment due to TEAEs.

Time frame:
Up to approximately 77 months
Reported as:
Geometric mean · Months
Time to Treatment Failure Due to Toxicity in pMMR Participants
MonthsLenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel
Time to Treatment Failure Due to Toxicity in pMMR Participants429.6 ± 491.6260.1 ± 356.2
SecondaryTime to Treatment Failure Due to Toxicity in All-comer Participants

Time to treatment failure due to toxicity was defined as the time from the date of randomization to the date a participant discontinued study treatment due to TEAEs.

Time frame:
Up to approximately 77 months
Reported as:
Geometric mean · Months
Time to Treatment Failure Due to Toxicity in All-comer Participants
MonthsLenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel
Time to Treatment Failure Due to Toxicity in All-comer Participants456.5 ± 520.6259.7 ± 369.5
SecondaryPlasma Concentration of Lenvatinib Versus Time in All-comer Participants

Pharmacokinetic (PK) samples were collected and analyzed using a population PK approach to estimate PK parameters. Individual predicted plasma concentration of lenvatinib was then derived from the PK model.

Time frame:
Cycle 1 day 1 0.5-4 hours (h), 6-10 postdose; Cycle 1 day 15 predose; Cycle 1 day 15 2-12h postdose, Cycle 2 day 1 predose, 0.5-4h, 6-10 h (Each cycle is 21 days)
Reported as:
Mean · nanograms per milliliter (ng/mL)
Plasma Concentration of Lenvatinib Versus Time in All-comer Participants
nanograms per milliliter (ng/mL)Lenvatinib 20 mg + Pembrolizumab 200 mg
Cycle 1 Day 1, 0.5-4h Post-dose152 ± 181
Cycle 1 Day 1, 6-10 h Post-dose258 ± 124
Cycle 1 Day 15, Pre-dose89.1 ± 69.6
Cycle 1 Day 15, 2-12 h Post-dose310 ± 218
Cycle 2 Day 1, Pre-dose67.2 ± 74.7
Cycle 2 Day 1, 0.5-4h151 ± 155
Cycle 2 Day 1, 6-10 h258 ± 138
SecondaryPlasma Concentration of Lenvatinib Versus Time in pMMR Participants

PK samples were collected and analyzed using a population PK approach to estimate PK parameters. Individual predicted plasma concentration of lenvatinib was then derived from the PK model.

Time frame:
Cycle 1 day 1 0.5-4 hour (h), 6-10 postdose; Cycle 1 day 15 predose; Cycle 1 day 15 2-12h postdose, Cycle 2 day 1 predose, 0.5-4h, 6-10 h (Each cycle is 21 days)
Reported as:
Mean · ng/mL
Plasma Concentration of Lenvatinib Versus Time in pMMR Participants
ng/mLLenvatinib 20 mg + Pembrolizumab 200 mg
Cycle 1 Day 1, 0.5-4 h Post-dose140 ± 180
Cycle 1 Day 1, 6-10 h Post-dose283 ± 136
Cycle 1 Day 15, Pre-dose93.8 ± 61.4
Cycle 1 Day 15, 2-12 h Post-dose335 ± 256
Cycle 2 Day 1, Pre-dose67.9 ± 60.9
Cycle 2 Day 1, 0.5-4 h153 ± 127
Cycle 2 Day 1, 6-10 h278 ± 132
SecondaryModel Predicted Apparent Total Clearance (CL/F) for Lenvatinib

Sparse pharmacokinetic (PK) samples were collected and analyzed using a population PK approach to estimate PK parameters. Individual predicted CL/F for lenvatinib was then derived from the PK model. The data was collected and analyzed for lenvatinib plus pembrolizumab arm only.

Time frame:
Cycle 1 Day 1: 0.5-10 hours post-dose; Cycle 1 Day 15: 0-12 hours post-dose; Cycle 2 Day 1: 0.5-10 hours post-dose (each cycle length=21 days)
Reported as:
Mean · liter per hour (L/h)
Model Predicted Apparent Total Clearance (CL/F) for Lenvatinib
liter per hour (L/h)Lenvatinib 20 mg + Pembrolizumab 200 mg
Model Predicted Apparent Total Clearance (CL/F) for Lenvatinib4.69 ± 1.39
SecondaryModel Predicted Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib

Sparse PK samples were collected and analyzed using a population PK approach to estimate PK parameters. Individual predicted AUC for lenvatinib was then derived from the PK model. The data was collected and analyzed for lenvatinib plus pembrolizumab arm only.

Time frame:
Cycle 1 Day 1: 0.5-10 hours post-dose; Cycle 1 Day 15: 0-12 hours post-dose; Cycle 2 Day 1: 0.5-10 hours post-dose (each cycle length=21 days)
Reported as:
Mean · nanogram*hour per milliliter (ng*h/mL)
Model Predicted Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib
nanogram*hour per milliliter (ng*h/mL)Lenvatinib 20 mg + Pembrolizumab 200 mg
Model Predicted Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib4134 ± 1350

Adverse events

Collected over Up to approximately 79 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
First Course: Lenvatinib + Pembrolizumab317/406 (78.1%)237/406 (58.4%)404/406 (99.5%)
First Course: TPC Doxorubicin or Paclitaxel362/388 (93.3%)121/388 (31.2%)379/388 (97.7%)
Second Course: Lenvatinib + Pembrolizumab8/21 (38.1%)4/21 (19%)20/21 (95.2%)
TPC Crossover1/6 (16.7%)1/6 (16.7%)6/6 (100%)
Most frequent serious events
Showing 10 of 276
Most frequent serious events
EventFirst Course: Lenvatinib + PembrolizumabFirst Course: TPC Doxorubicin or PaclitaxelSecond Course: Lenvatinib + PembrolizumabTPC Crossover
Adrenal insufficiencyEndocrine disorders3/4060/3880/211/6
PneumoniaInfections and infestations6/4064/3880/211/6
MalaiseGeneral disorders0/4060/3880/211/6
Renal disorderRenal and urinary disorders0/4060/3880/211/6
ColitisGastrointestinal disorders7/4061/3881/210/6
Decreased appetiteMetabolism and nutrition disorders9/4060/3881/210/6
HyponatraemiaMetabolism and nutrition disorders2/4062/3881/210/6
Ischaemic enteritisGastrointestinal disorders0/4060/3881/210/6
General physical health deteriorationGeneral disorders3/4061/3881/210/6
ArteriosclerosisVascular disorders0/4060/3881/210/6
Most frequent other events
Showing 10 of 118
Most frequent other events
EventFirst Course: Lenvatinib + PembrolizumabFirst Course: TPC Doxorubicin or PaclitaxelSecond Course: Lenvatinib + PembrolizumabTPC Crossover
HypothyroidismEndocrine disorders238/4063/3884/214/6
DysphoniaRespiratory, thoracic and mediastinal disorders95/4063/3880/214/6
HypertensionVascular disorders255/40620/3881/212/6
DiarrhoeaGastrointestinal disorders223/40676/3884/213/6
NauseaGastrointestinal disorders212/406179/3881/212/6
VomitingGastrointestinal disorders149/40680/3882/213/6
Weight decreasedInvestigations147/40623/3881/213/6
Decreased appetiteMetabolism and nutrition disorders184/40683/3884/213/6
HypomagnesaemiaMetabolism and nutrition disorders80/40627/3882/213/6
Pain in extremityMusculoskeletal and connective tissue disorders55/40622/3881/213/6

Baseline characteristics

The Intention-to-treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(years)Lenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice (TPC): Doxorubicin or PaclitaxelTotal
Mean63.2 ± 9.163.8 ± 9.263.5 ± 9.1
Age, Customized
Age, Customized(Participants)Lenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice (TPC): Doxorubicin or PaclitaxelTotal
In utero000
Preterm newborn infants (gestational age < 37 wks)000
Newborns (0-27 days)000
Infants and toddlers (28 days-23 months)000
Children (2-11 years)000
Adolescents (12-17 years)000
Adults (18-64 years)206204410
From 65-84 years205210415
85 years and over022
Sex: Female, Male
Sex: Female, Male(Participants)Lenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice (TPC): Doxorubicin or PaclitaxelTotal
Female411416827
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice (TPC): Doxorubicin or PaclitaxelTotal
Hispanic or Latino5973132
Not Hispanic or Latino309288597
Unknown or Not Reported435598
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice (TPC): Doxorubicin or PaclitaxelTotal
American Indian or Alaska Native4711
Asian8592177
Native Hawaiian or Other Pacific Islander101
Black or African American171431
White261247508
More than one race71320
Unknown or Not Reported364379
Eastern Cooperative Oncology Group (ECOG) performance status
Eastern Cooperative Oncology Group (ECOG) performance status(Participants)Lenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice (TPC): Doxorubicin or PaclitaxelTotal
0 = Fully active; no performance restrictions246241487
1 = Limited activity, ambulant, can-do light work165175340
Prior history of pelvic radiation
Prior history of pelvic radiation(Participants)Lenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice (TPC): Doxorubicin or PaclitaxelTotal
Participants with pelvic radiation176187363
Participants without pelvic radiation235229464
Geographic region
Geographic region(Participants)Lenvatinib 20 mg + Pembrolizumab 200 mgTreatment of Physician's Choice (TPC): Doxorubicin or PaclitaxelTotal
Region 1234240474
Region 2177176353

1 further baseline measures are reported on the registry.

08

Study locations

169 sites
  • Arizona Oncology Associates, PC- HAL
    Phoenix, Arizona 85016, United States
  • University of California San Francisco
    San Francisco, California 94158, United States
  • University of California Los Angeles
    Santa Monica, California 90095, United States
  • Smilow Cancer Hospital at Yale New Haven
    New Haven, Connecticut 06510, United States
  • University of Miami Health System
    Miami, Florida 33136, United States
  • Florida Hospital Cancer Institute
    Orlando, Florida 32804, United States
  • Georgia Cancer Center at Augusta University
    Augusta, Georgia 30912, United States
  • North Shore University Health System
    Evanston, Illinois 60201, United States
  • University Medical Center New Orleans
    New Orleans, Louisiana 70112, United States
  • Greater Baltimore Medical Center
    Baltimore, Maryland 21204, United States
  • Maryland Oncology Hematology, P.A.
    Wheaton, Maryland 20902, United States
  • John Theurer Cancer Center at Hackensack University Med Ctr
    Hackensack, New Jersey 07601, United States
  • Holy Name Medical Center
    Teaneck, New Jersey 07666, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10022, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Willamette Valley Cancer Institute and Research Center
    Eugene, Oregon 97401, United States
  • Sanford Gynecology Oncology
    Sioux Falls, South Dakota 57104, United States
  • UT West Cancer Center
    Germantown, Tennessee 38138, United States
  • Texas Oncology-South Austin
    Austin, Texas 78745, United States
  • University of Texas Southwestern Medical Center at Dallas
    Dallas, Texas 75390-9032, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Texas Oncology-San Antonio Medical Center
    San Antonio, Texas 78240, United States
  • Utah Cancer Specialists
    Salt Lake City, Utah 84106, United States
  • Centro de Oncologia e Investigacion Buenos Aires COIBA
    Berazategui, Buenos Aires B1884BBF, Argentina
  • Hospital Privado de la Comunidad
    Mar del Plata, Buenos Aires B7602CBM, Argentina
  • Instituto de Investigaciones Metabolicas
    Buenos Aires, C1012AAR, Argentina
  • Hospital Aleman
    Buenos Aires, C1118AAT, Argentina
  • Instituto de Oncologia Angel H. Roffo
    Buenos Aires, C1417DTB, Argentina
  • Instituto Medico Especializado Alexander Fleming
    Buenos Aires, C1426ANZ, Argentina
  • Centro Oncologico Riojano Integral
    La Rioja, F5300COE, Argentina
  • Royal North Shore Hospital
    Sydney, New South Wales 2065, Australia
  • Royal Brisbane and Women s Hospital
    Herston, Queensland 4029, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • St John of God
    Subiaco, Western Australia 6008, Australia
  • Hospital Araujo Jorge
    Goiânia, Goiás 74175-120, Brazil
  • Instituto Nacional do Cancer II
    Rio de Janeiro, Rio de Janeiro 20220-410, Brazil
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Fundacao Dr Amaral Carvalho
    Jaú, São Paulo 17210-080, Brazil
  • Instituto do Cancer de Sao Paulo - ICESP
    São Paulo, São Paulo 01246-000, Brazil
  • Clinica de Pesquisas e Ctro de Estudos Onc. Ginecol. e Mamaria Ltda
    São Paulo, São Paulo 01317-000, Brazil
  • Faculdade de Medicina da Universidade Federal de Minas Gerais
    Belo Horizonte, 30130-100, Brazil
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • Cancer Care Manitoba
    Winnipeg, Manitoba R3E 0V9, Canada
  • London Health Sciences Centre
    London, Ontario N6A 5W9, Canada
  • Ottawa General Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • Sunnybrook Health Science Centre
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
  • CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont
    Montreal, Quebec H1T 2M4, Canada
  • Centre Hospitalier de l Universite de Montreal - CHUM
    Montreal, Quebec H2X 3E4, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • CIUSSS de l'Estrie-CHUS
    Sherbrooke, Quebec J1H 5N4, Canada
  • CHU de Quebec-Universite Laval-Hotel Dieu de Quebec
    Québec, G1R 2J6, Canada
  • Clinica del Country
    Bogota, Cundinamarca 110221, Colombia
  • Fundacion Valle del Lili
    Cali, Valle del Cauca Department 760032, Colombia
  • Biomelab S A S
    Barranquilla, 08002, Colombia
  • Clinica Colsanitas S.A. - Sede Clinica Universitaria Colombia
    Bogotá, 111321, Colombia
  • Rodrigo Botero SAS
    Medellín, 50015, Colombia
  • Fundacion Colombiana de Cancerologia Clinica Vida
    Medellín, 50032, Colombia
  • Oncomedica S.A.
    Montería, 230002, Colombia
  • Institut Bergonie
    Bordeaux, 33076, France
  • Centre de Lutte Contre le Cancer Francois Baclesse
    Caen, 14076, France
  • Centre Oscar Lambret
    Lille, 59020, France
  • Centre Leon Berard
    Lyon, 69008, France
  • Institut Regional du Cancer de Montpellier - ICM
    Montpellier, 34298, France
  • Hopital prive du Confluent
    Nantes, 44277, France
  • Groupe Hospitalier Broca Cochin Hotel Dieu
    Paris, 75014, France
  • Hopital Diaconesses Croix Saint Simon
    Paris, 75020, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, 69310, France
  • Centre Armoricain de Radiotherapie Imagerie medicale et Oncologie
    Plérin, 22190, France
  • Centre Eugene Marquis
    Rennes, 35042, France
  • Institut Gustave Roussy
    Villejuif, 94800, France
  • EISAI Trial Site 4
    Berlin, Germany
  • EISAI Trial Site 2
    Dresden, Germany
  • EISAI Trial Site 1
    Erlangen, Germany
  • EISAI Trial Site 6
    Hamburg, Germany
  • EISAI Trial Site 3
    Rostock, Germany
  • EISAI Trial Site 5
    Tübingen, Germany
  • Mater Misericordiae University Hospital
    Dublin, D07 R2WY, Ireland
  • Soroka Medical Center
    Beersheba, 84101, Israel
  • Rambam Medical Center
    Haifa, 3525408, Israel
  • Edith Wolfson Medical Center
    Holon, 5822012, Israel
  • Hadassah Medical Center. Ein Kerem
    Jerusalem, 9112001, Israel
  • Rabin Medical Center
    Petah Tikva, 4941492, Israel
  • Chaim Sheba Medical Center
    Ramat Gan, 5262000, Israel
  • Azienda Ospedaliera per l Emergenza Cannizzaro
    Catania, 95126, Italy
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
    Meldola, 47014, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milan, 20133, Italy
  • Ospedale San Raffaele
    Milan, 20132, Italy
  • Istituto Europeo di Oncologia
    Milan, 20141, Italy
  • Istituto Nazionale Tumori IRCCS Fondazione Pascale
    Naples, 80131, Italy
  • Policlinico Universitario Agostino Gemelli
    Roma, 168, Italy
  • EISAI Trial Site 9
    Nagoya, Aichi-ken, Japan
  • EISAI Trial Site 18
    Kashiwa, Chiba, Japan
  • EISAI Trial Site 7
    Matsuyama, Ehime, Japan
  • EISAI Trial Site 15
    Tōon, Ehime, Japan
  • EISAI Trial Site 5
    Kurume, Fukoka, Japan
  • EISAI Trial Site 11
    Sapporo, Hokkaido, Japan

Showing the first 100 of 169 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Marth C, Lorusso D, Bidzinski M, Scollo P, Vardar MA, Oaknin A, Kaen DL, Nogueira-Rodrigues A, Miller DS, Hasegawa K, MacKay H, Moore RG, Santin AD, Yunokawa M, Romero I, Pignata S, Baron-Hay S, Kim YM, Amit A, Ghamande S, Danska-Bidzinska A, Tarnawski R, Wang PH, Yu Z, Slomovitz BM, Okpara CE, McKenzie J, Meng R, Orlowski R, Makker V. Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes. Int J Gynecol Cancer. 2026 Jul;36(7):104693. doi: 10.1016/j.ijgc.2026.104693. Epub 2026 Apr 12. PubMed 42167105 ↗
  • Yonemori K, Fujiwara K, Hasegawa K, Yunokawa M, Ushijima K, Suzuki S, Shikama A, Minobe S, Usami T, Kim JW, Kim BG, Wang PH, Chang TC, Yamamoto K, Han S, McKenzie J, Orlowski RJ, Miura T, Makker V, Man Kim Y. Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer. J Gynecol Oncol. 2024 Mar;35(2):e40. doi: 10.3802/jgo.2024.35.e40. Epub 2024 Jan 19. PubMed 38302725 ↗
  • Colombo N, Lorusso D, Monk BJ, Slomovitz B, Hasegawa K, Nogueira-Rodrigues A, Zale M, Okpara CE, Barresi G, McKenzie J, Makker V. Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab. Oncologist. 2024 Jan 5;29(1):25-35. doi: 10.1093/oncolo/oyad201. PubMed 37523661 ↗
  • Lorusso D, Colombo N, Herraez AC, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay SE, Ray-Coquard IL, Shapira-Frommer R, Kim YM, McCormack M, Massaad R, Nguyen AM, Zhao Q, McKenzie J, Prabhu VS, Makker V. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice. Eur J Cancer. 2023 Jun;186:172-184. doi: 10.1016/j.ejca.2023.03.015. Epub 2023 Mar 23. PubMed 37086595 ↗
  • Makker V, Colombo N, Casado Herraez A, Monk BJ, Mackay H, Santin AD, Miller DS, Moore RG, Baron-Hay S, Ray-Coquard I, Ushijima K, Yonemori K, Kim YM, Guerra Alia EM, Sanli UA, Bird S, Orlowski R, McKenzie J, Okpara C, Barresi G, Lorusso D. Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775. J Clin Oncol. 2023 Jun 1;41(16):2904-2910. doi: 10.1200/JCO.22.02152. Epub 2023 Apr 14. PubMed 37058687 ↗
  • Makker V, Colombo N, Casado Herraez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D; Study 309-KEYNOTE-775 Investigators. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19. PubMed 35045221 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Mar 2022, 44 months.

Of 44 phase 3 interventional studies under Endometrial Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 126. This study's 44 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2018
First posted
May 7, 2018
StartActual
Jun 11, 2018
Primary completionActual
Mar 1, 2022
CompletionActual
Feb 26, 2025
Results first posted
Nov 17, 2021
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03517449
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
May 7, 2018
Start date
Jun 11, 2018
Primary completion
Mar 1, 2022
Completion
Feb 26, 2025
Results posted
Nov 17, 2021
Last update
Mar 19, 2026

Study contacts

Medical Director
study director · Eisai Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pembrolizumab · Lenvatinib

Start the discussion